1Takahashi T, Hagowara A, Shimotsuma M, et al. Prophylaxis and treatment of peritoneal carcinomatosis: intraperitoneal chemotherapy with mitomycin C bound to activated carbon particles [ J ]. World J Surg, 1995,19: 265.
5Sugarbaker PH, Cunliffe WJ, Belliveau J, et al. Rationale for intergrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer [ J ]. Semin Oncol, 1989,16(1) : 83.
4Takahashi T, Hagowara A, Shimotsuma M, et al. Prophylaxis and treatment of peritoneal eareinomatosis: intraperitoneal chemotherapy with mitomycin C bound to activated carbon particles[J]. World J Surg, 1995,19 : 265.
5Sugarbaker PH. Rational for early postoperation intraperitoneal chemotherapy as a surgical adjuvant for gastrointestinal malignancy[J]. Regul Cancer Treat, 1989,66.
6Archer S, Gray B. Intraperitoneal 5-fluorouracil infusion for treatment of both peritoneal and liver micrometastases[J]. Sergery, 1990,108(3) :502.
7Surgarbaker PH, Graves T, Debrujin EA, et al. Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatoses from gastrointestinal cancer: pharmacological studies [ J ]. Cancer Res, 1990, 108(3) : 5790.
8Dudar JE. Differential response of normal and tumor microcirculation hyperthrmia[J]. Cancer Res, 1994,44:605.
9Tamplins W. Hyperthermic enhancement of antibody complement cytotoxicity for human cells [J]. J Nat Cancer Inst, 1981,66:453.
10Elias D,El Otmany A,Bonnay M,et al.Human pharmacokinetic study of heated intraperitoneal oxaliplatin in increasingly hypotonic solutions after complete resection of peritoneal carcinomatosis.Oncology,2002,63:346-352.
